Immuneering Announces Participation in November Investor Conferences
Immuneering Corporation (Nasdaq: IMRX) announced participation in three investor conferences in November 2022 to discuss its pipeline and business strategy. CEO Ben Zeskind and CSO Brett Hall will present at the Jefferies London Healthcare Conference on November 15, the Piper Sandler Healthcare Conference on November 29, and the Evercore ISI HealthCONx Conference on December 1. The company is advancing its lead candidate, IMM-1-104, currently in a Phase 1/2a trial for tumors with RAS mutations, aiming for targeted cancer treatment.
- Participation in three notable investor conferences, increasing visibility and engagement with investors.
- Advancing lead product candidate IMM-1-104 in Phase 1/2a clinical trials, indicating progress in drug development.
- No specific financial metrics or results from ongoing clinical trials detailed, leaving uncertainty about progress.
- Forward-looking statements convey inherent risks in drug development, including potential delays or failures.
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will participate in three November investor conferences to share commentary around the Company’s pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer.
Immuneering will participate in the following conferences:
Jefferies London Healthcare Conference, London, England
Format: Fireside Chat
Date: November 15, 2022
Time: 12:55-1:25 pm CET
34 Annual Piper Sandler Healthcare Conference, New York, NY
Format: Formal Presentation
Date: November 29, 2022
Time: 10:30-10:55 am ET
5th Annual Evercore ISI HealthCONx Conference, Virtual
Format: Fireside Chat
Date: December 1, 2022
Time: 9:40-10:00 am ET
The audio portions of the presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering's disease-agnostic discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Immuneering is evaluating its lead product candidate, IMM-1-104, in a Phase 1/2a clinical trial in advanced solid tumors with RAS mutations (NCT05585320). IMM-1-104 aims to achieve pan-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells. IMM-1-104 is designed to be a highly selective third generation dual MEK inhibitor that modulates the signaling dynamics of the MAPK pathway by driving deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, normalizing level of signaling designed to spare healthy cells. IMM-1-104 is translationally guided by Immuneering's proprietary, human-aligned 3D tumor modeling platform combined with patient aligned bioinformatics. In addition to IMM-1-104, Immuneering is currently evaluating IMM-6-415 in IND-enabling studies. The earlier Immuneering drug discovery pipeline includes five additional oncology programs as well as two neuroscience programs.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the treatment potential of IMM-1-104 and IMM-6-415, the timing of commencement and enrollment of the Phase 1/2a clinical trial for IMM-1-104, the design, enrollment criteria and conduct of the Phase 1/2a clinical trial, the timing of submission of the IND and commencement of clinical trials for IMM-6-415 and Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-Q filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.
Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
617-500-8080
rkusko@immuneering.com
Investor Contact:
Susan A. Noonan
S.A. Noonan Communications
917-513-5303
susan@sanoonan.com
FAQ
What is Immuneering Corporation's stock symbol?
When will Immuneering participate in investor conferences?
What is the focus of Immuneering's lead product candidate IMM-1-104?
Where can I find the audio portions of Immuneering's conference presentations?
What are the potential risks mentioned by Immuneering in their press release?
